We are live on ! Find out more
CNCE

Concert Pharmaceuticals, Inc.
CNCE

Delisted

CNCE was delisted on the 3rd of March, 2023.

Back to rankings

114 hedge funds and large institutions have $423M invested in Concert Pharmaceuticals, Inc. in 2017 Q4 according to their latest regulatory filings, with 47 funds opening new positions, 37 increasing their positions, 23 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

327% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 11

93% more capital invested

Capital invested by funds: $219M → $423M (+$204M)

61% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 23

59% more call options, than puts

Call options by funds: $1.22M | Put options by funds: $769K

44% more funds holding

Funds holding: 79 → 114 (+35)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
114
Holders Change
+35
Holders Change %
+44.3%
% of All Funds
2.59%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
47
Increased
37
Reduced
23
Closed
11
Calls
$1.22M
Puts
$769K
Net Calls
+$452K
Net Calls Change
+$80K

Top Buyers

Rank Fund Capital Flow
1
LCM
Laurion Capital Management
New York
+$14.3M
2
BlackRock
BlackRock
New York
+$13.1M
3
Millennium Management
Millennium Management
New York
+$10.1M
4
BC
Boxer Capital
California
+$8.05M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$6M

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$26.9M
2
BI
BVF Inc
California
-$23.5M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$5.43M
4
LSC
Lyon Street Capital
California
-$5.21M
5
SM
Senvest Management
New York
-$4.82M
Name Holding Trade Value Shares
Change 		Change in
Stake
Jane Street
76
Jane Street
New York
$451K +$351K +17,421 New
RhumbLine Advisers
77
RhumbLine Advisers
Massachusetts
$446K -$64.4K -3,200 -16%
PCM
78
Princeton Capital Management
New Jersey
$411K +$320K +15,882 New
SPIA
79
Steward Partners Investment Advisory
New York
$404K +$214K +10,650 +213%
AAM
80
Aureus Asset Management
Massachusetts
$404K +$315K +15,625 New
GAM
81
Gotham Asset Management
New York
$402K +$313K +15,530 New
ProShare Advisors
82
ProShare Advisors
Maryland
$386K +$301K +14,931 New
Balyasny Asset Management
83
Balyasny Asset Management
Illinois
$377K +$60.4K +3,000 +26%
CAM
84
ClariVest Asset Management
California
$370K +$288K +14,318 New
Manulife (Manufacturers Life Insurance)
85
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$366K -$21.1K -1,047 -7%
AllianceBernstein
86
AllianceBernstein
Tennessee
$357K +$26.2K +1,300 +10%
State of Wisconsin Investment Board
87
State of Wisconsin Investment Board
Wisconsin
$336K – – –
AIMCA
88
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$329K +$256K +12,700 New
AIG
89
American International Group
New York
$312K +$1.15K +57 +0.5%
Royal Bank of Canada
90
Royal Bank of Canada
Ontario, Canada
$274K +$180K +8,956 +543%
PO
91
Private Ocean
California
$259K +$201K +10,000 New
MIM
92
MetLife Investment Management
New Jersey
$232K +$181K +8,973 New
VOYA Investment Management
93
VOYA Investment Management
Georgia
$227K +$177K +8,778 New
NI
94
Numeric Investors
Massachusetts
$207K +$161K +8,000 New
QT
95
Quantbot Technologies
New York
$170K +$133K +6,608 New
MLICM
96
Metropolitan Life Insurance Company (MetLife)
New York
$164K +$128K +6,348 New
Zurich Cantonal Bank
97
Zurich Cantonal Bank
Switzerland
$147K +$18.9K +940 +20%
Legal & General Group
98
Legal & General Group
United Kingdom
$118K -$17.4K -862 -16%
Citigroup
99
Citigroup
New York
$117K +$14K +696 +18%
Ohio Public Employees Retirement System (OPERS)
100
Ohio Public Employees Retirement System (OPERS)
Ohio
$101K +$78.5K +3,898 New
1 2 3
4
5

CNCE Hedge Fund Activity: Q4 2017 in Review

114 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q4 2017, worth a combined $423M — up 93% from $219M a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new CNCE positions and 11 closed out — a net gain of 36 holders — while 37 added to existing stakes and 23 trimmed.

The largest buyer was Laurion Capital Management, opening a new position worth an estimated $14.3M. The largest seller was Great Point Partners, cutting an estimated $26.9M.

  • 114 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q4 2017, up from 79 in Q3 2017.
  • Funds reported $423M of Concert Pharmaceuticals, Inc. stock for Q4 2017, up 93% quarter-over-quarter.
  • 47 funds opened new Concert Pharmaceuticals, Inc. positions in Q4 2017 and 11 closed out, a net change of +36 holders.
  • The largest Concert Pharmaceuticals, Inc. buyer in Q4 2017 was Laurion Capital Management, an estimated $14.3M added.
  • The largest Concert Pharmaceuticals, Inc. seller in Q4 2017 was Great Point Partners, an estimated $26.9M sold.

Based on aggregated 13F filings for Q4 2017.